$SNY has released its earnings report, highlighting a strong performance for Q4 2024 with net sales up by 10.3% to €10.6 billion, continuing a trend of double-digit growth. Major products like Dupixent and Beyfortus are serving as growth drivers, while the gross margin is slightly down to 74.3%. Future risks include potential price competition and regulatory uncertainties.